ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. is a commercial-stage medical device company focused on developing and commercializing platforms for minimally invasive surgical procedures in the brain. Its primary offering is the ClearPoint system, which includes hardware (head fixation frame, computer workstation, in-room monitor), disposables (SmartFrame trajectory device, hand controller, SmartFlow Neuro cannula), and software that guides physicians in surgical planning, device alignment, navigation, and procedure monitoring. The company also offers the ClearPoint Prism Neuro laser therapy system for tissue necrotization or coagulation, and the IRRAflow system, an active fluid exchange platform. Additionally, ClearPoint Neuro provides consulting services to pharmaceutical and medical technology partners, including benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from preclinical to clinical settings.

ClearPoint Neuro, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CLPT. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Solana Beach, California, and its operations are primarily focused on the U.S. market, though it may engage with international partners through licensing and collaboration agreements.

ClearPoint Neuro operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical device company, it develops and commercializes platforms for minimally invasive brain surgeries. Its products include the ClearPoint system for surgical navigation and laser ablation, as well as the IRRAflow system for fluid exchange. The company's focus on neurosurgical devices places it at the intersection of medical technology and neurology, serving hospitals and surgical centers that perform brain procedures.

ClearPoint Neuro, Inc. is headquartered in Solana Beach, California, United States. It primarily serves the U.S. market, as indicated by its focus on the United States in its description. The company has licenses and collaboration agreements with international partners, including Koninklijke Philips N.V. (Netherlands), UCB Biopharma SRL (Belgium), Clinical Laserthermia Systems AB (Sweden), and the University of California, San Francisco, and NE Scientific, LLC (both U.S.). These partnerships suggest a global reach in research and development, but its commercial operations are centered in the U.S.

ClearPoint Neuro generates revenue through the sale of its ClearPoint system components, including hardware, disposables, and software licenses. The company also earns from its ClearPoint Prism Neuro laser therapy system and the IRRAflow active fluid exchange platform. Additionally, it provides consulting services to pharmaceutical and medical technology partners, offering benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation services. These services help partners develop and bring new therapies to market, creating a recurring revenue stream. The company's business model combines product sales with service-based collaborations, leveraging its expertise in minimally invasive neurosurgery.